Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Published in Intensive Care Medicine, Inotrem's results highlight the pivotal role of the soluble TREM-1 biomarker in identifying high-risk septic shock patients and guiding targeted treatment with nangibotide. Paris, July 23 rd – Inotrem, a clinical-stage biotechnology company specialized in immunotherapy for acute inflammatory conditions, announces the publication of its precision medicine strategy for its leading drug candidate nangibotide, a first-in-class TREM-1 inhibitor in septic shock. This work has been published in Intensive Care Medicine , one of the most prestigious journals in the field of critical care medicine. The article, titled “A mechanism-based prognostic enrichment strategy for the development of the TREM-1 inhibitor nangibotide in septic shock,” confirms the central role of the soluble TREM-1 (sTREM-1) biomarker as a valuable precision medicine tool in acute care. High levels of this marker identify the most critically ill patients developing severe organ fa
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Is FDA's Fast Subcutaneous Lunsumio VELO Approval Reshaping the Investment Case For Roche (SWX:ROG)? [Yahoo! Finance]Yahoo! Finance
- FDA approves Roche's Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular LymphomaBusiness Wire
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance]Yahoo! Finance
- Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships? [Yahoo! Finance]Yahoo! Finance